8:10 AM ET
8-K
Business Update
Cingulate Business Update
Cingulate Inc. provided a regulatory update on its lead ADHD asset, CTx-1301, following a previously received FDA Complete Response Letter (CRL). The company has substantially completed the required manufacturing work to address the FDA's requests and expects to resubmit its New Drug Application (NDA) between December 2026 and January 2027.